Navigation Links
UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting
Date:4/3/2008

YOQNEAM, Israel and SAN RAMON, California, April 3 /PRNewswire/ -- Results of an independent multi-treatment clinical study of the UltraShape(R) Contour I, the first clinically proven non-invasive solution for fat reduction and body contouring using non-thermal selective focused ultrasound will be presented at the American Society for Laser Medicine and Surgery annual meeting on April 4, 2008 in Kissimmee, Florida. The presentation is entitled "Lipotripsy: Non-invasive Ultrasonic Selective Destruction of Adipocytes using UltraShape" will take place during the scientific session The Cutting Edge in Optical Diagnostics and Therapeutics of Tissues and Cells.

Hector Leal-Silva, M.D., a dermatologic surgeon based in Monterrey, Mexico, will present the results of the 36 patient clinical study using the UltraShape system on localized fat deposits in the abdomen, flanks, and thighs. The study showed definitive, measurable results in 100 percent of patients including an average of two-inch (5cm) reduction in circumference in the abdomen after a series of three treatments, one month apart. CT scans taken in a subset of study subjects showed objective quantifiable fat thickness reduction. Photographic assessment, weight and circumferential measures were evaluated before and after each treatment and one month after the last treatment. Visual contour improvement was seen in over 85% of patients as assessed by an independent panel of physicians. Ninety-four percent (94%) of patients were satisfied with the procedure. In addition, there were no adverse events reported.

"With the major shift in patient demand toward non-invasive, pain-free, no-downtime procedures UltraShape has become a core procedure offering in my aesthetic practice," said Leal. "My clinical study demonstrated measurable circumference reduction and visual improvement in body contour in all patients. Moreover, my patients are happy with a high percentage of them returning for treatment of other body areas or recommending UltraShape to friends and family."

"Dr. Leal-Silva's impressive clinical study results combined with his successful commercial experience with UltraShape further adds to our growing body of evidence supporting UltraShape as the clinically proven non-invasive option for the reduction of localized fat deposits and improvement in body contour," said Rodger Stewart, President and Chief Executive Officer of UltraShape Inc.

About the UltraShape(R) Contour I

The UltraShape Contour I system, based on patented focused ultrasound technology, is the first scientifically and clinically proven non-invasive fat reduction and body contouring solution for both men and women. The device produces mechanical, non-thermal, acoustic effects which target and selectively destroy fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software guarantees adherence to a pre-determined treatment algorithm minimizing risk of contour irregularities, a common side effect of liposuction. The UltraShape procedure is performed during a convenient, "walk-in, walk-out" session carried out in an office-based environment; it requires no anesthesia or sedation, and the vast majority of patients report no pain or discomfort. After treatment, patients immediately resume their daily routines with no need for maintenance treatments. The UltraShape procedure is available in 50 countries and over 55,000 patient treatments have been performed worldwide with high patient satisfaction. The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The UltraShape Contour I system is not available for sale in the United States.

About UltraShape(R)

UltraShape is redefining aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for body contouring. The company is dedicated to providing clinically proven safe and effective solutions that enhance the lives of patients worldwide. The UltraShape proprietary non-invasive body contouring technology is based on focused ultrasound that targets and selectively disrupts fat cells without affecting surrounding structures. Founded in 2000, UltraShape is a privately held and venture backed company with offices in the United States, Israel, France, United Kingdom, and Italy. For more information visit http://www.ultrashape.com.

Contact:

Abigail Marks Paula Moggio Jessica Fishman

UltraShape FischerHealth Gitam Porter Novelli

+972-4-909-9260 +1-310-577-7870 x151 +972-3-576-5798

abigail@ultrashape.com pmoggio@fischerhealth.com jessica@gitam.co.il


'/>"/>
SOURCE UltraShape Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
2. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
3. American Laser Center Offers VelaShape Body Shaping and Cellulite Reduction Treatment
4. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
5. FreshFx Recognized for use in the Scalder as a Solution to the Yield/Pathogen Reduction Dilemma
6. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
7. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
8. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
9. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
10. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
11. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
Breaking Medicine Technology:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
Breaking Medicine News(10 mins):